Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Chosa

    MCap

    SEK57m

    Last close

    SEK0.80

    ▲ 0.20 (33.33%)

    Vection Technologies

    MCap

    AUD47m

    Last close

    AUD0.04

    ▲ 0.00 (12.90%)

    Metro Bank

    MCap

    GBP684m

    Last close

    GBP1.02

    ▲ 7.90 (8.43%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

SynBiotic (SCALE: SBX)

Last close As at 23/11/2024

EUR5.44

▲ −0.06 (−1.09%)

Market capitalisation

EUR26m

SynBiotic is an investment vehicle that pursues an EU-focused buy-and-build approach. The core business of the platform company is the R&D of new cannabinoid and terpene-based solutions for the health issues of pain, sleep and anxiety.

Latest Insights

View More

Consumer | Outlook

SynBiotic — Platform primed for growth

Consumer | Outlook

SynBiotic — Building the platform

Consumer | Update

SynBiotic — Management update – on track

Consumer | Update

SynBiotic — Further acquisitions
Visit Website

Sector

Consumer

Equity Analyst

Russell Pointon

Russell Pointon

Director of Content, Consumer and Media

Key Management

  • Daniel Kruse

    CEO

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (6.5) (9.8) 82.1
Relative (3.3) (12.9) 52.4
52 week high/low €13.9/€2.9

Financials

SynBiotic has built up a leading platform company that spans the hemp and cannabis industry to cover the full value chain, from cultivation through to sales. Management buys and builds ventures that create and market hemp, cannabis and cannabinoid products for both medical and recreational use, while continually seeking investments in exciting new verticals. Recreational cannabis use has recently been partially legalised in Germany, while the same legislative changes have benefited the medicinal market. Having built its platform prior to these changes, SynBiotic is seeing its investments bear fruit and we believe it is well-positioned for any further relaxation in cannabis legalisation in Germany.

Research

thematic

Consumer

Deutsches Eigenkapitalforum (EKF) 2023 consumer and media

thematic

Consumer

ConsumerWatch – Falling into the fall

thematic

Consumer

ConsumerWatch – Making the most of the summer

thematic

Consumer

ConsumerWatch – A Spring in the step

thematic

Consumer

ConsumerWatch – January sales

thematic

Consumer

ConsumerWatch – Bargains galore

thematic

Consumer

IPO apocalypse

thematic

Consumer

Food tech – At the forefront of food innovation

thematic

TMT

ESG, moving beyond the box tick

thematic

Consumer

ConsumerWatch – Value emerging

thematic

Consumer

Circular economy business models

thematic

Consumer

Seven things every investor should know about Unbound Group

thematic

Consumer

Moving from a vegan January to a sustainable one

thematic

Consumer

Cultivated meat – Engineering the growth of alternative meats

thematic

Consumer

The future of fish – The investment case for sustainable fishing

thematic

Consumer

The growth of UK food ordering and delivery platform

thematic

Consumer

Meating Demand – The lean, green money-making machine

thematic

Consumer

Illuminator: August Update

thematic

Consumer

Deutsche Börse Eigenkapitalforum 2014 Research Guide